Clinical Outcomes for Hospitalized Patients with Legionella Pneumonia in the Antigenuria Era: The Influence of Levofloxacin Therapy
|
|
- Dwight Allison
- 6 years ago
- Views:
Transcription
1 MAJOR ARTICLE Clinical Outcomes for Hospitalized Patients with Legionella Pneumonia in the Antigenuria Era: The Influence of Levofloxacin Therapy Analía Mykietiuk, 1 Jordi Carratalà, 1 Núria Fernández-Sabé, 1 Jordi Dorca, 2 Ricard Verdaguer, 3 Frederic Manresa, 2 and Francesc Gudiol 1 1 Infectious Disease, 2 Respiratory Medicine, and 3 Microbiology Services, Institut d Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, University of Barcelona, Barcelona, Spain Background. Although the reduction in case-fatality rate recently observed among patients with Legionella pneumonia has been largely attributed to the progressive utilization of urine antigen testing, other factors, such as changes in empirical antibiotic therapy, may also have contributed. We have analyzed more-recent outcomes of Legionella pneumonia in an institution where urine antigen testing was reflexly performed in cases of communityacquired pneumonia without an etiological diagnosis. Methods. From a prospective series of 1934 consecutive cases of community-acquired pneumonia in nonimmunocompromised adults, 139 cases of Legionella pneumophila pneumonia were selected for observational review. Legionella cases were analyzed for outcome with respect to antibiotic, mortality, complications, length of stay, time to defervescence, and stability. Results. The early case-fatality rate was 2.9% (4 of 139 patients), and the overall case-fatality rate was 5% (7 of 139 patients). One hundred twenty patients (86.3%) received an appropriate initial therapy, which included macrolides (i.e., erythromycin or clarithromycin) in 80 patients and levofloxacin in 40. Levofloxacin progressively replaced macrolides as the initial therapy during the study period. Compared with patients who received macrolides, patients who received levofloxacin had a faster time to defervescence (2.0 vs. 4.5 days; P!.001) and to clinical stability (3 vs. 5 days; P p.002). No differences were found regarding the development of complications (25% vs. 25%; P p.906) and case-fatality rate (2.5% vs. 5%; P p.518 ). The median length of hospital stay was 8 days in patients treated with levofloxacin and 10 days in those who received macrolides ( P p.014 ). Conclusions. Legionella pneumonia is still associated with significant complications in hospitalized patients, but recent mortality is substantially lower than that found in earlier series. Levofloxacin may produce a faster clinical response than older macrolides, allowing for shorter hospital stay. Legionella pneumophila is a leading cause of community-acquired pneumonia [1 5]. It has been estimated that ,000 people are hospitalized with legionellosis annually in the United States [6]. Moreover, Legionella is particularly frequent among patients with community-acquired pneumonia who require admission to an intensive care unit [7, 8]. Classically, L. pneumophila has been classified as a high-risk pathogen in community-acquired pneumo- Received 20 September 2004; accepted 28 October 2004; electronically published 17 February Reprints or correspondence: Dr. Jordi Carratalà, Infectious Disease Service, Hospital Universitari de Bellvitge, Feixa Llarga s/n, L Hospitalet, Barcelona, Spain (jcarratala@csub.scs.es). Clinical Infectious Diseases 2005; 40: by the Infectious Diseases Society of America. All rights reserved /2005/ $15.00 nia, accounting for substantial morbidity and with casefatality rates of 5% 25% among immunocompetent hosts [1, 9 12]. However, a recent surveillance study [13] showed a remarkable reduction in case-fatality rates during the past decade, suggesting that new models of management may have improved outcomes in patients with Legionella pneumonia. Although it is reasonable to suppose that early recognition of Legionella pneumonia by means of urine antigen testing may have contributed to decreasing mortality, the impact of other factors, including new antibiotic options, is less clear. Furthermore, to assess more adequately the role of these factors, outcome measures other than mortality should be considered [14]. In this study, we analyzed more recent clinical outcomes of Legionella pneumonia, including response to antibiotic therapy, time to clinical stability, develop- 794 CID 2005:40 (15 March) Mykietiuk et al.
2 ment of in-hospital complications, length of stay, and mortality in an institution where urine antigen testing was consistently performed during the study period. METHODS Setting and study design. The study was conducted at a 900- bed university hospital for adults in Barcelona, Spain (Hospital Universitari de Bellvitge). The hospital serves an urban area of 1,100,000 inhabitants and has 24,000 admissions annually. All 1934 non severely immunosuppressed patients with community-acquired pneumonia admitted to the hospital between 13 February 1995 and 31 December 2003 were prospectively recruited and followed up. Patients with neutropenia (i.e., those with a granulocyte count of! cells/l), those with AIDS, and transplant recipients were not included. The definition of pneumonia and hospitalization criteria have been described elsewhere [5]. For the purposes of the present observational study, we analyzed data on 139 cases of Legionella pneumonia, diagnosed with use of 1 of the following methods: urine antigen test; isolation of Legionella in sputum, transthoracic needle aspiration specimen, or pleural fluid; and/or a 4-fold increase in the antibody titer. We compared clinical outcomes for patients treated with levofloxacin with outcomes for those who received macrolides. Clinical evaluation, antibiotic therapy, and follow-up. At the initial visit to the emergency department, patients gave a complete clinical history, underwent physical examination, and underwent chemical and hematological testing. Microbiological studies included blood cultures and sputum Gram stain and culture, when available. A urine antigen test for Legionella species was performed at hospital admission, if indicated by the attending physician, but was performed 48 h after admission for all patients for whom nonetiological diagnosis had been made (reflex testing). Paired serum samples were obtained during the acute and convalescent phases of infection (separated by a 3 8 week interval) for serological studies. Antibiotic therapy was initiated in the emergency department in accordance with hospital guidelines, which recommended the administration of a b-lactam (either ceftriaxone or amoxicillin-clavulanate, administered intravenously) with or without a macrolide (either erythromycin 1000 mg iv q.i.d. or clarithromycin 500 mg iv b.i.d.); from 1998 onward, levofloxacin (500 mg iv q.d.) was also allowed. Patients with a urine antigen test result positive for Legionella at admission were treated with a macrolide (with or without rifampin, on the basis of physician preference) or levofloxacin. Those patients initially treated with other antibiotics were switched to appropriate therapy. Recommended duration of therapy was days. Patients were seen daily during their hospital stay by 1 of the investigators, who provided medical advice when requested and stored clinical data in a computer-assisted protocol. All patients were evaluated for adverse events. Assessments included evaluation of changes in vital signs, clinical laboratory results, and physical examination findings. A long-term followup visit took place 1 month after discharge. Definitions. To stratify patients into risk classes, we used the validated prediction rule, calculated according to the pneumonia severity index (PSI) [15]. The time to overall clinical stability was defined as the time required for 5 vital signs to became stable (temperature, 37.2 C; heart rate, 100 beats/ min; respiratory rate, 24 breaths/min; systolic blood pressure, 90 mm Hg; oxygen saturation on room air, 190%) with normalization of mental status and the ability to eat [16]. A variable was considered stable if all measurements in a 24-h period met stability criteria. Complications were defined as any untoward circumstance occurring during hospitalization, with the exception of the side effects of the. Length of hospital stay was calculated as the time from the admission date to the date of discharge from the hospital. Early case-fatality rate was defined as death (as proportion of cases) due to any cause 48 h after hospitalization. Overall case-fatality rate was defined as death (as proportion of cases) due to any cause 30 days after hospitalization. Microbiologic studies. Investigation of pathogens in blood, normally sterile fluids, sputum, and other samples was performed using standard microbiological procedures. L. pneumophila serogroup 1 antigen in urine was detected by an immunoenzymetric commercial method (Legionella Urinary Antigen; Binax). Isolation of Legionella species was attempted in sputum samples and other respiratory samples by the selective medium buffered charcoal yeast extract-a. EIA was used to detect antibodies against L. pneumophila serogroups 1 6. Statistical analysis. To detect significant differences between antibiotic groups, we used the x 2 test with continuity correction for categorical variables and the Student s t test or the Mann-Whitney U test for continuous variables, when appropriate. In all analyses, P values!.05 were considered to be statistically significant. RESULTS During the study period, 1934 non severely immunosuppressed adults with community-acquired pneumonia were admitted to our institution. L. pneumophila was the causative organism in 139 (7.2%) of the cases. The diagnosis was established with use of 1 of the following methods: urine antigen test (in 120 cases), seroconversion (in 80), and/or positive culture (in 43). Culture results were positive for 32 of 59 cases in which sputum samples were available, in 9 of 14 cases in which transthoracic needle aspiration specimens were available, and in 2 of 10 cases in which pleural fluid Outcomes of Legionella Pneumonia CID 2005:40 (15 March) 795
3 samples were available. All cases identified by culture corresponded to L. peumophila serogroup 1. Only 19 cases were diagnosed by serological methods alone. Two cases of mixed infection were detected (1 case of Chlamydia pneumoniae infection and 1 case of Chlamydia psittaci infection). Cases were uniformly distributed during the study period. Figure 1 shows the total number of cases distributed every 3 years and the number of patients who underwent urine antigen testing in that period, which was also constant. One hundred twenty (86.3%) of the 139 patients with Legionella pneumonia were men, with a mean age ( SD) of years. Seventy-one (51.1%) of the patients were smokers, and 59 (42.4%) had a history of alcohol abuse. Twenty-five patients (17.9%) had been immunized with influenza vaccine for the influenza season, and 8 (5.8%) had received 23-valent pneumococcal capsular polysaccharide vaccine in the 5 years before admission to the hospital. Seventy-four patients (53.2%) had underlying diseases, mainly chronic heart disease (in 25 patients), diabetes mellitus (in 20), chronic obstructive pulmonary disease (in 15), chronic liver disease (in 6), and cancer (in 5). Five patients (3.6%) had a history of long-term steroid use. Sixty-three patients (45.3%) had received antibiotic therapy before hospitalization (mainly b-lactam antibiotics [in 56 cases]). Sixty-four patients (46%) were classified into high-risk pneumonia classes (risk classes IV V) according to PSI score. One hundred twenty (86.3%) of the patients received an appropriate initial therapy, which included levofloxacin for 40 patients and macrolides for the remaining 80 patients (erythromycin for 53 patients and clarithromycin for 27 patients). Forty-eight patients who were treated with macrolides were also given rifampin. Ten (25%) of the patients in the levofloxacin group and 21 (26.2%) in the macrolide group received steroids for the current episode of pneumonia ( P p.883). Levofloxacin progressively replaced macrolides as the initial therapy during the study (figure 1). Eighteen patients (13%) received an inappropriate empirical therapy with b-lactam antibiotics, which was promptly modified to cover Legionella when the result of the urine antigen test was available; all of these patients remained febrile at the time they were switched to macrolides (13 patients) or levofloxacin (5 patients). One additional patient received initial therapy with both levofloxacin and clarithromycin. As shown in table 1, demographic and clinical characteristics were similar when comparing patients treated initially with levofloxacin or macrolides. There were no differences between groups regarding the presence at baseline of significant prognostic factors, such as age 170 years, presence of comorbid conditions, hypoalbuminemia, renal insufficiency, and multilobar pneumonia. The mean partial pressure of oxygen breathing room air at admission to the hospital was similar in the 2 groups (59.72 mm Hg vs mm Hg; P p.950). The percentage of patients classified into high-risk pneumonia classes according to PSI score (i.e., those with 190 points) did not differ between groups (42.5% vs. 47.5%; P p.688). The mean duration of intravenous therapy ( SD) was days for patients treated with levofloxacin and days for those treated with macrolides ( P p.043). Complete duration of antibiotic therapy ( SD) was days and days, respectively ( P p.004). Table 2 shows the main clinical outcomes for patients treated with either levofloxacin or macrolides. As can be seen, patients receiving levofloxacin had a faster time to defervescence and to resolution of cough. No difference was observed in time to resolution of chest pain between the 2 groups. Patients treated with levofloxacin achieved overall clinical stability significantly earlier than did patients treated with macrolides (3.0 vs. 5.0 days). Figure 1. Data for patients hospitalized with Legionella pneumonia in Spain, Levofloxacin, cases treated with levofloxacin; LP, cases of Legionella pneumonia; macrolides, cases treated with macrolides; mortality, mortality associated with Legionella pneumonia; urinary antigen test, cases of Legionella pneumonia confirmed with use of urine antigen testing. 796 CID 2005:40 (15 March) Mykietiuk et al.
4 Table 1. Baseline characteristics of 120 patients with community-acquired Legionella pneumonia treated with either levofloxacin or macrolides. Variable Lvfx group (n p 40) Macrolide group a (n p 80) P Age, mean years SD Age 170 years 7 (17.5) 13 (16.2).862 Male sex 36 (90) 69 (86.2).558 Alcohol consumption 180 g per day 17 (42.5) 37 (46.2).697 Smoking 20 (50) 41 (51.2).845 Previous antibiotic therapy 2 (5) 9 (11.2).263 Comorbid condition 14 (35) 27 (33.7).892 Hypoalbuminemia b 14 (35) 40 (50).127 Renal insufficiency c 7 (17.5) 9 (11.2).341 Partial pressure of oxygen breathing room air, mean mm Hg SD Multilobar pneumonia 18 (45) 35 (43.7).804 Pleural effusion 5 (12.5) 14 (17.5).477 Pneumonia severity index, mean score SD High-risk pneumonia d All 17 (42.5) 38 (47.5).688 Risk class IV 13 (32.5) 26 (32.5).723 Risk class V 4 (10 ) 12 (15).723 Admission to the ICU 5 (12.5) 2 (2.5).783 NOTE. Data are no. (%) of patients, unless otherwise indicated. ICU, intensive care unit; Lvfx, levofloxacin. a Forty-eight patients who were treated with macrolides also received rifampin. b Albumin level,!3 g/dl. c Serum creatinine level, 11.5 mg/dl. d Pneumonia severity index, 190 points (i.e., risk classes IV and V). As shown in table 2, there were no significant differences between groups regarding the development of complications, which occurred in 25% of both antibiotic groups. The most frequent complications were respiratory failure and a worsening of comorbid conditions. The median length of hospital stay was significantly shorter for patients treated with levofloxacin. The length of stay for other patients with pneumonia did not change significantly over the study period, ranging from a mean of days in 1995 to a mean of in No differences in outcome between patients who received either erythromycin or clarithromycin or patients who received regimens that included rifampin were observed. The incidence of -related adverse events was similar for the 2 groups, occurring in 8 (20%) of 40 patients in the levofloxacin group, compared with 24 (30%) of 80 patients in the macrolide group ( P p.243). All of the drugrelated adverse events were minor, the most common events being phlebitis (occurring in 12.5% of patients in the levofloxacin group, compared with 10% of patients in the macrolide group), gastrointestinal disorders (5% vs. 5%), liver function test abnormalities (2.5% vs. 3.7%), and rash (2.5% vs. 3.7%). When considering the total number of patients with Legionella pneumonia, the early case-fatality rate was 2.9% (4 of 139 patients), and the overall case-fatality rate was 5% (7 of 139 patients). No patients died during the last 3 years of the study (0 of 46 patients). As shown in table 2, early and overall casefatality rates did not differ significantly between patients receiving levofloxacin and those receiving macrolides. Although there was a trend towards a lower case-fatality rate in the levofloxacin group, small numbers of fatal cases of pneumonia may produce type II error. Among patients who received an initial inappropriate empirical therapy, the early case-fatality rate was 5.5% (1 of 18 patients), and the overall case-fatality rate was 11.1% (2 of 18 patients). DISCUSSION The present study offers a detailed analysis of clinical outcomes for a large series of patients with community-acquired Legionella pneumonia documented in recent years in a single institution. Clinical management and diagnostic evaluation of patients with community-acquired pneumonia, including urine antigen testing, did not undergo substantial changes during the study period, although levofloxacin has progressively replaced Outcomes of Legionella Pneumonia CID 2005:40 (15 March) 797
5 Table 2. Clinical outcomes for 120 patients with community-acquired Legionella pneumonia treated with either levofloxacin or macrolides. Clinical outcome Lvfx group (n p 40) Macrolide group a (n p 80) P Time to defervescence, days b!.001 Mean SD Median (IQR) 2.0 ( ) 4.50 ( ) Time to resolution of cough, days!.001 Mean SD Median (IQR) 3.0 ( ) 5.0 ( ) Time to resolution of chest pain, days.893 Mean SD Median (IQR) 3.0 ( ) 3.0 ( ) Time to achieve clinical stability, days.002 Mean SD Median (IQR) 3.0 ( ) 5.0 ( ) In-hospital complications c Any 10 (25) 20 (25).906 Respiratory failure 4 (10) 12 (15).507 Worsening of comorbid conditions 5 (12.5) 6 (7.5).371 Acute renal failure 3 (7.5) 6 (7.5) Length of hospital stay, days.014 Mean SD Median (IQR) 8.0 ( ) 10.0 ( ) Early case-fatality rate d 0 3 (3.7).550 Overall case-fatality rate e 1 (2.5) 4 (5).518 NOTE. Data are no. (%) of patients, unless otherwise indicated. IQR, interquartile range; Lvfx, levofloxacin. a Forty-eight patients who were treated with macrolides also received rifampin. b Temperature, 37.0 C. c Some patients had 11 complication. d Death!48 h after admission. e Death!30 days after admission. macrolides as the initial therapy for Legionella pneumonia since Benin et al. [13] recently reported data from a large-scale study by the Centers for Disease Control and Prevention showing a decrease in the case-fatality rate for community-acquired Legionella pneumonia from 26% to 10% for the period These investigators observed a relationship between the increasing use of urine antigen testing as a useful diagnostic tool for Legionella pneumonia and the sustained decrease in mortality. However, they stated that improvement in empirical antibiotic s, promoted by the implementation of community-acquired pneumonia guidelines, could be another reason for the reduction in mortality. We observed a low casefatality rate throughout the entire study period; this low rate was more evident during the last 3 years of the study period, when levofloxacin accounted for most initial s (figure 1). This finding is in accordance with some recent case studies of patients with Legionella pneumonia who received diagnoses by means of urine antigen testing; these case studies have reported case-fatality rates of 0% 5% [9, 17, 18]. Although there have been no prospective controlled trials addressing the subject, some authorities have recommended therapy with fluoroquinolones or azithromycin, rather than with older macrolides, for the of Legionella pneumonia [1]. Indeed, these agents have been shown to be better than erythromycin in inhibiting the intracellular growth of L. pneumophila, both in vitro and in animal models [19 22]. In this regard, Yu et al. [18] have reported a successful experience with levofloxacin therapy in 75 hospitalized and ambulatory patients with Legionella pneumonia who were identified through a database of patients enrolled in 6 trials involving community-acquired pneumonia. Similarly, Plouffe et al. [17] reported similar results using azithromycin in an open, noncomparative trial involving 25 hospitalized patients with Legionella pneumonia who had significant comorbidities. Both studies indicate that use of these highly active agents may 798 CID 2005:40 (15 March) Mykietiuk et al.
6 shorten the duration of antibiotic, although neither study analyzed outcomes other than clinical response (i.e., cure, improvement, or failure) and safety. In our study, we observed a nonsignificant trend toward a lower case-fatality rate in patients who received levofloxacin therapy. However, there were significant differences favoring levofloxacin in important outcomes other than mortality, such as time to defervescence, time to overall clinical stability, duration of antibiotic, and length of hospital stay. These data provide evidence about the safety of an early switch from intravenous to oral levofloxacin for of Legionella pneumonia and suggest that the use of agents with enhanced activity against Legionella species may result in a faster resolution of clinical signs and symptoms. Moreover, they provide valuable information in terms of better understanding the continuous improvement in Legionella pneumonia outcomes following the generalized use of urine antigen testing. Because our study is not randomized, the possible superiority of levofloxacin therapy over therapy with the older macrolides should be interpreted with caution. It is possible that concomitant early recognition of Legionella and a trend toward levofloxacin in the past few years coincided to produce less morbidity and fewer fatalities and that levofloxacin is not a better than macrolides. A prospective, randomized trial comparing therapy with the more effective macrolide, azithromycin, with levofloxacin therapy is warranted. However, it seems unlikely that any randomized trials involving the antibiotic of Legionella pneumonia will be possible in the near future [23, 24]. In summary, our data show that, although Legionella pneumonia continues to be associated with significant morbidity in hospitalized patients, the current mortality rate is substantially lower than that traditionally reported. Furthermore, our findings suggest that levofloxacin therapy produces a faster clinical response than does therapy with the older macrolides, allowing a shorter length of hospital stay. Acknowledgments Financial support. Fondo de Investigación Sanitaria de la Seguridad Social (grants 98/0783 and 00/0438); Institut d Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Universitari de Bellvitge ( ; to A.M.); University of Barcelona, Beca de Formació en la Recerca i la Docència (2000; to N.F.-S). Potential conflicts of interest. All authors: no conflicts. References 1. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of communityacquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: Stout JE, Yu VL. Legionellosis. N Engl J Med 1997; 337: File TM Jr. Community-acquired pneumonia. Lancet 2003; 362: Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine (Baltimore) 1990; 69: Rosón B, Carratalà J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of communityacquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001; 33: Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalizations: results of a population-basedactive surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997; 157: Rello J, Bodi M, Mariscal D, et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003; 123: Vergis EN, Yu VL. New directions for future studies of communityacquired pneumonia: optimizing impact on patient care. Eur J Clin Microbiol Infect Dis 1999; 18: Lettinga KD, Verbon A, Weverling GJ, et al. Legionnaires disease at Dutch flower show: prognostic factors and impact of therapy. Emerg Infect Dis 2002; 8: Lieberman D, Porath A, Schlaeffer F, Lieberman D, Boldur I. Legionella species community acquired pneumonia: a review of 56 hospitalizedadult patients. Chest 1996; 109: Yu VL, Kroboth FJ, ShonnardJ, Brown A, McDearman S, Magnussen M. Legionaires disease: new clinical perspective from a prospective pneumonia study. Am J Med 1982; 73: Fernandez-Sabé N, Rosón B, Carratalà J, Dorca J, Manresa F, Gudiol F. Clinical diagnosis of Legionella pneumonia revisited: evaluation of the Community-Based Pneumonia Incidence Study Group Scoring System. Clin Infect Dis 2003; 37: Benin AL, Benson RF, Besser RE. Trends in legionnaires disease, : declining mortality and new patterns of diagnosis. Clin Infect Dis 2002; 35: Barlow GD, Lamping DL, Davey PG, Nathwani D. Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians and policy-makers. Lancet Infect Dis 2003; 3: Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify lowrisk patients with community-acquired pneumonia. N Engl J Med 1997; 336: Halm EA, Fine MJ, Marrie TJ, et al Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: Plouffe JF, Breiman RF, Fields BS, et al. Azithromycin in the of Legionella pneumonia requiring hospitalization. Clin Infect Dis 2003; 37: Yu VL, Greenberg RN, Zadeikis N, et al. Levofloxacin efficacy in the of community-acquired Llegionellosis. Chest 2004; 125: Meyer RD. Role of the quinolones in the of legionellosis. J Antimicrob Chemother 1991; 28: Jonas D, Engels I, Friedhoff C, Spitzmüller B, Daschner FD, Frank U. Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. J Antimicrob Chemother 2001; 47: Baltch AL, Smith RP, Franke MA, Michelsen PB. Antibacterial effects of levofloxacin, erythromycin and rifampin in a human monocyte system against Legionella pneumophila. Antimicrob Agents Chemother 1998; 42: Edelstein PH, Edelstein MA, Lehr KH, Ren J. In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother 1996; 37: Edelstein PH. Antimicrobial chemotherapy for legionnaires disease: time for a change. Ann Intern Med 1998; 129: Fields BS, Benson RF, Besser RE. Legionella and legionnaire s disease: 25 years of investigation. Clin Microbiol Rev 2002; 15: Outcomes of Legionella Pneumonia CID 2005:40 (15 March) 799
ORIGINAL INVESTIGATION. Health Care Associated Pneumonia Requiring Hospital Admission. Epidemiology, Antibiotic Therapy, and Clinical Outcomes
ORIGINAL INVESTIGATION Health Care Associated Pneumonia Requiring Hospital Admission Epidemiology, Antibiotic Therapy, and Clinical Outcomes Jordi Carratalà, MD, PhD; Analía Mykietiuk, MD; Núria Fernández-Sabé,
More informationMAJOR ARTICLE. Beatriz Rosón, 1 Jordi Carratalà, 1 Jordi Dorca, 2 Aurora Casanova, 3 Frederic Manresa, 2 and Francesc Gudiol 1
MAJOR ARTICLE Etiology, Reasons for Hospitalization, Risk Classes, and Outcomes of Community-Acquired Pneumonia in Patients Hospitalized on the Basis of Conventional Admission Criteria Beatriz Rosón, 1
More informationAntimicrobial Chemotherapy for Legionnaires Disease: Levofloxacin versus Macrolides
MAJOR ARTICLE Antimicrobial Chemotherapy for Legionnaires Disease: Levofloxacin versus Macrolides Rosa Mª Blázquez Garrido, 1 Francisco Javier Espinosa Parra, 1 Loreto Alemany Francés, 2 Rosa Mª Ramos
More informationProspective Study of the Usefulness of Sputum Gram Stain in the Initial Approach to Community-Acquired Pneumonia Requiring Hospitalization
869 Prospective Study of the Usefulness of Sputum Gram Stain in the Initial Approach to Community-Acquired Pneumonia Requiring Hospitalization Beatriz Rosón, Jordi Carratalà, Ricard Verdaguer, Jordi Dorca,
More informationCommunity-Acquired Pneumonia OBSOLETE 2
Community-Acquired Pneumonia OBSOLETE 2 Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with respect to appropriate
More informationEarly mortality in patients with communityacquired pneumonia: causes and risk factors
Eur Respir J 2008; 32: 733 739 DOI: 10.1183/09031936.00128107 CopyrightßERS Journals Ltd 2008 Early mortality in patients with communityacquired : causes and risk factors C. Garcia-Vidal*, N. Fernández-Sabé*,
More informationAntimicrobial Stewardship in Community Acquired Pneumonia
Antimicrobial Stewardship in Community Acquired Pneumonia Medicine Review Course 2018 Dr Lee Tau Hong Consultant Department of Infectious Diseases National Centre for Infectious Diseases Scope 1. Diagnosis
More informationImportance of Atypical Pathogens of Community-Acquired Pneumonia
S35 Importance of Atypical Pathogens of Community-Acquired Pneumonia Joseph F. Plouffe Departments of Internal Medicine and Medical Microbiology and Immunology, Ohio State University College of Medicine,
More informationImpact of pre-hospital antibiotic use on community-acquired pneumonia
ORIGINAL ARTICLE INFECTIOUS DISEASE Impact of antibiotic use on community-acquired pneumonia A. F. Simonetti 1, D. Viasus 1,2, C. Garcia-Vidal 1,2, S. Grillo 1, L. Molero 1, J. Dorca 3,4 and J. Carratala
More informationWORKSHOP. The Multiple Facets of CAP. Community acquired pneumonia (CAP) continues. Jennifer s Situation
Practical Pointers pointers For for Your your Practice practice The Multiple Facets of CAP Dr. George Fox, MD, MSc, FRCPC, FCCP Community acquired pneumonia (CAP) continues to be a significant health burden
More informationMaking the Right Call With. Pneumonia. Community-acquired pneumonia (CAP) is a. Community-Acquired. What exactly is CAP?
Making the Right Call With Community-Acquired Pneumonia In this article: By Thomas J. Marrie, MD The case of Allyson Allyson, 32, presented to the emergency department with a 48-hour history of anorexia,
More informationTrends in Legionnaires Disease, : Declining Mortality and New Patterns of Diagnosis
MAJOR ARTICLE Trends in Legionnaires Disease, 1980 1998: Declining Mortality and New Patterns of Diagnosis Andrea L. Benin, a Robert F. Benson, and Richard E. Besser Respiratory Diseases Branch, Division
More informationKAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA
KAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA Methodology: Expert opinion Issue Date: 8-97 Champion: Pulmonary Medicine Most Recent Update: 6-08, 7-10, 7-12 Key Stakeholders: Pulmonary Medicine,
More informationPneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes
1 Infectious Disease Department of Hospital Universitari de Bellvitge, Institut d Investigació Biomèdica de Bellvitge (IDIBELL), Spanish Network for the Research in Infectious Diseases (REIPI), University
More informationEpidemiology and Etiology of Community-Acquired Pneumonia 761 Lionel A. Mandell
LOWER RESPIRATORY TRACT INFECTIONS Preface Thomas M. File, Jr xiii Community-Acquired Pneumonia: Pathophysiology and Host Factors with Focus on Possible New Approaches to Management of Lower Respiratory
More informationDuration of antibiotic treatment and symptom recovery in community-acquired pneumonia El Moussaoui, R.
UvA-DARE (Digital Academic Repository) Duration of antibiotic treatment and symptom recovery in community-acquired pneumonia El Moussaoui, R. Link to publication Citation for published version (APA): El
More informationRepeated Pneumonia Severity Index Measurement After Admission Increases its Predictive Value for Mortality in Severe Community-acquired Pneumonia
ORIGINAL ARTICLE Repeated Pneumonia Severity Index Measurement After Admission Increases its Predictive Value for Mortality in Severe Community-acquired Pneumonia Chiung-Zuei Chen, 1 Po-Sheng Fan, 2 Chien-Chung
More informationSporadic and epidemic community legionellosis: two faces of the same illness
Eur Respir J 2007; 29: 138 142 DOI: 10.1183/09031936.00077206 CopyrightßERS Journals Ltd 2007 Sporadic and epidemic community legionellosis: two faces of the same illness N. Sopena*, L. Force #, M.L. Pedro-Botet*,
More informationSupplementary Online Content
Supplementary Online Content Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory
More informationCommunity-acquired pneumonia in adults
Prim Care Clin Office Pract 30 (2003) 155 171 Community-acquired pneumonia in adults Julio A. Ramirez, MD a,b, * a Department of Medicine, University of Louisville School of Medicine, 512 S. Hancock Street,
More informationCharles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center
Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center Kathy Peters is a 63 y.o. patient that presents to your urgent care office today with a history
More informationLegionnaire s disease is a febrile illness with pneumonia. The Radiologic Manifestations of Legionnaire s Disease*
The Radiologic Manifestations of Legionnaire s Disease* Michael J. Tan, MD; James S. Tan, MD, FCCP; Robert H. Hamor, MD; Thomas M. File, Jr., MD, FCCP; Robert F. Breiman, MD; and the Ohio Community-Based
More informationSupplementary Online Content
Supplementary Online Content Uranga A, España, Bilbao A, et al. Duration of antibiotic treatment in communityacquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med. ublished online
More informationPneumococcal Pneumonia: Update on Therapy in the Era of Antibiotic Resistance
a of Antibiotic Resistance March 01, 2003 By Bernard Karnath, MD [1], Akua Agyeman, MD [2], and Albert Lai, MD [3] Sir William Osler once called pneumococcal pneumonia the captain of the men of death.
More informationEpidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease
Nephrol Dial Transplant (2011) 26: 2899 2906 doi: 10.1093/ndt/gfq798 Advance Access publication 27 January 2011 Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney
More informationJCP Online First, published on June 17, 2013 as /jclinpath Original article
JCP Online First, published on June 17, 2013 as 10.1136/jclinpath-2012-201209 Original article Diagnostic, therapeutic and economic consequences of a positive urinary antigen test for Legionella spp. in
More informationHigh-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia
High-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia Review Andrew F. Shorr, MD, MPH, FCCP Department of Medicine Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington,
More informationCommunity Acquired Pneumonia. Background & Rationale to North American Guidelines. Lionel Mandell MD FRCPC Brussels Belgium
Community Acquired Pneumonia Background & Rationale to North American Guidelines Lionel Mandell MD FRCPC Brussels Belgium Consider Impact of the disease Issues to reflect upon Impact of the Disease 3-4
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone
More informationImpact of rapid urine antigen tests to determine the etiology of community-acquired pneumonia in adults
Respiratory Medicine (2006) 100, 884 891 Impact of rapid urine antigen tests to determine the etiology of community-acquired pneumonia in adults Felipe Andreo a,, José Domínguez b, Juan Ruiz a, Silvia
More informationLower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone
Eur J Clin Microbiol Infect Dis (2005) 24: 190 195 DOI 10.1007/s10096-005-1295-9 ARTICLE E. García Vázquez J. Mensa J. A. Martínez M. A. Marcos J. Puig M. Ortega A. Torres Lower mortality among patients
More informationHow do we define pneumonia?
Robert L. Keith MD FCCP Associate Professor of Medicine Division of Pulmonary Sciences & Critical Care Medicine Denver VA Medical Center University of Colorado Denver How do we define pneumonia? Fever
More informationCommunity Acquired Pneumonia. Abdullah Alharbi, MD, FCCP
Community Acquired Pneumonia Abdullah Alharbi, MD, FCCP A 68 y/ male presented to the ED with SOB and productive coughing for 2 days. Reports poor oral intake since onset due to nausea and intermittent
More informationTHIS IS AN OFFICIAL NH DHHS HEALTH ALERT
THIS IS AN OFFICIAL NH DHHS HEALTH ALERT Distributed by the NH Health Alert Network Health.Alert@nh.gov August 25, 2018 0800 EDT NH-HAN 20180825 Cluster of Legionella pneumophila Pneumonia (Legionnaire
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Azithromycin (Zedbac ) 500 mg powder for solution for infusion. Reference number: 2476 LIMITED SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Azithromycin (Zedbac ) 500 mg powder for solution for infusion Reference number: 2476 LIMITED SUBMISSION This report has been prepared by the All Wales Therapeutics
More informationClinical failure, community-acquired pneumonia, management, outcome, prognosis, risk-factors
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01535.x Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia M. Hoogewerf 1, J. J. Oosterheert 1, E. Hak 2, I. M.
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationCare Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: All MHS employed providers within Primary Care, Urgent Care, and In-Hospital Care. The secondary audience
More informationReceived 3 August 2005/Returned for modification 13 September 2005/Accepted 13 January 2006
CLINICAL AND VACCINE IMMUNOLOGY, Mar. 2006, p. 361 364 Vol. 13, No. 3 1556-6811/06/$08.00 0 doi:10.1128/cvi.13.3.361 364.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Evaluation
More informationOpen Access RESEARCH ARTICLE. Research article. BioMed Central
RESEARCH ARTICLE Open Access Research article Clinical features and predictors of mortality in admitted patients with community- and hospital-acquired legionellosis: A Danish historical cohort study Sanne
More informationCharles Feldman. Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand
Opportunistic Infections Community Acquired Pneumonia Charles Feldman Professor of Pulmonology and Chief Physician Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand Introduction
More informationIs Azithromycin the First-Choice Macrolide for Treatment of Community-Acquired Pneumonia?
MAJOR ARTICLE Is Azithromycin the First-Choice Macrolide for Treatment of Community-Acquired Pneumonia? F. Sánchez, 1 J. Mensa, 1 J. A. Martínez, 1 E. García, 1 F. Marco, 1 J. González, 1 M. A. Marcos,
More informationA Comparative Study of Community-Acquired Pneumonia Patients Admitted to the Ward and the ICU*
CHEST Original Research A Comparative Study of Community-Acquired Pneumonia Patients Admitted to the Ward and the ICU* Marcos I. Restrepo, MD, MSc, FCCP; Eric M. Mortensen, MD, MSc; Jose A. Velez, MD;
More informationMAJOR ARTICLE. (See the editorial commentary by Mandell on pages 386 8)
MAJOR ARTICLE Severe Community-Acquired Pneumonia: Validation of the Infectious Diseases Society of America/ American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission Adamantia Liapikou,
More informationMAJOR ARTICLE. Atypical Pneumonia in Thailand CID 2007:45 (15 December) e147
MAJOR ARTICLE Epidemiology of Severe Pneumonia Caused by Legionella longbeachae, Mycoplasma pneumoniae, and Chlamydia pneumoniae: 1-Year, Population- Based Surveillance for Severe Pneumonia in Thailand
More informationThe IDSA/ATS consensus guidelines on the management of CAP in adults
The IDSA/ATS consensus guidelines on the management of CAP in adults F. Piffer F. Tardini R. Cosentini U.O. Medicina d'urgenza, Gruppo NIV, Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina
More informationEvaluation of the Oxoid Xpect Legionella test kit for Detection of Legionella
JCM Accepts, published online ahead of print on 6 May 2009 J. Clin. Microbiol. doi:10.1128/jcm.00397-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationCARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: The target audience for this Care Guideline is all MultiCare providers and staff, including those associated with our clinically integrated
More informationSerological evidence of Legionella species infection in acute exacerbation of COPD
Eur Respir J 2002; 19: 392 397 DOI: 10.1183/09031936.02.00256702 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Serological evidence of Legionella
More informationHigh-Dose, Short-Course Levofloxacin for Community-Acquired Pneumonia: A New Treatment Paradigm
MAJOR ARTICLE High-Dose, Short-Course Levofloxacin for Community-Acquired Pneumonia: A New Treatment Paradigm Lala M. Dunbar, 1 Richard G. Wunderink, 2 Michael P. Habib, 3 Leon G. Smith, 4 Alan M. Tennenberg,
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia Paladino J A, Gudgel L D, Forrest A, Niederman
More informationBrice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine
Brice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine Discuss advances in predicting prognosis Understand dwhat we know (and don t know) about the Microbiology Recognize important
More informationKey words: bacteremia; community-acquired pneumonia; comorbid condition; diabetes mellitus; empyema; etiology; outcome; pleural effusion
Etiology and Outcome of Community- Acquired Pneumonia in Patients With Diabetes Mellitus* Miquel Falguera, MD; Ricard Pifarre, MD; Antonio Martin, MD; Anas Sheikh, MD; and Anna Moreno, MD Study objectives:
More informationMicrobiology of Atypical Pneumonia. Dr. Mohamed Medhat Ali
Microbiology of Atypical Pneumonia Dr. Mohamed Medhat Ali Pneumonia P n e u m o n i a i s a n infection of the lungs that can be caused by viruses, bacteria, and fungi. Atypical! Pneumonia Symptoms. X-ray
More informationORIGINAL INVESTIGATION. Azithromycin vs Cefuroxime Plus Erythromycin for Empirical Treatment of Community-Acquired Pneumonia in Hospitalized Patients
ORIGINAL INVESTIGATION Azithromycin vs Cefuroxime Plus Erythromycin for Empirical Treatment of Community-Acquired Pneumonia in Hospitalized Patients A Prospective, Randomized, Multicenter Trial Emanuel
More informationCAP, HCAP, HAP, VAP. 1. In 1898, William Osler described community-acquired pneumonia as:
1. In 1898, William Osler described community-acquired pneumonia as: Brad Sharpe, M.D. Professor of Clinical Medicine Department of Medicine UCSF sharpeb@medicine.ucsf.edu I have no relevant financial
More informationCommunity acquired pneumonia due to Legionella pneumophila in a tertiary care hospital
101 Research article Community acquired pneumonia due to Legionella pneumophila in a tertiary care hospital Abstract BN Dissanayake 1,, DE Jayawardena 2, CG Senevirathna 1, TM Gamage 1 Sri Lankan Journal
More informationPCR Is Not Always the Answer
PCR Is Not Always the Answer Nicholas M. Moore, PhD(c), MS, MLS(ASCP) CM Assistant Director, Division of Clinical Microbiology Assistant Professor Rush University Medical Center Disclosures Contracted
More informationA prospective comparison of nursing home acquired pneumonia with community acquired pneumonia
Eur Respir J 2001; 18: 362 368 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 A prospective comparison of nursing home acquired pneumonia
More informationRespiratory Infections
Respiratory Infections NISHANT PRASAD, MD THE DR. JAMES J. RAHAL, JR. DIVISION OF INFECTIOUS DISEASES NEWYORK-PRESBYTERIAN QUEENS Disclosures Stockholder: Contrafect Corp., Bristol-Myers Squibb Co Research
More informationSupplementary Online Content
Supplementary Online Content Lee JS, Nsa W, Hausmann LRM, et al. Quality of care for elderly patients hospitalized for pneumonia in the United States, 2006 to 2010. JAMA Intern Med. Published online September
More informationJAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections
Journal of Antimicrobial Chemotherapy (1998) 41, Suppl. B, 69 73 JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections G. Tatsis*, G.
More informationRapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults
Eur Respir J 2003; 21: 209 214 DOI: 10.1183/09031936.03.00058802 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2003 European Respiratory Journal ISSN 0903-1936 Rapid urinary antigen test
More informationClinical characteristics of health care-associated pneumonia in a Korean teaching hospital
Respiratory Medicine (2010) 104, 1729e1735 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Clinical characteristics of health care-associated pneumonia in a Korean teaching
More informationAcute Respiratory Infection. Dr Anthony Gibson
Acute Respiratory Infection Dr Anthony Gibson Range of Conditions Upper tract Common Cold coryza Sore Throat- Pharyngitis Sinusitis Epiglottitis Range of Conditions Lower Acute Bronchitis Acute Exacerbation
More informationPCR Is Not Always the Answer
PCR Is Not Always the Answer Nicholas M. Moore, PhD, MS, MLS(ASCP) CM Assistant Director, Division of Clinical Microbiology Assistant Professor Rush University Medical Center Disclosures Contracted research:
More informationCurrent and Emerging Legionella Diagnostics
Current and Emerging Legionella Diagnostics Nicole Wolter Centre for Respiratory Diseases and Meningitis (CRDM) National Institute for Communicable Diseases nicolew@nicd.ac.za 7 th FIDSSA Conference, Cape
More informationGuidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)
RECOMMENDATIONS OF THE SPANISH SOCIETY OF PULMONOLOGY AND THORACIC SURGERY (SEPAR) Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia. Spanish Society of Pulmonology and Thoracic
More informationIn vitro and Intracellular Activities of Peptide Deformylase. Inhibitor GSK against Legionella pneumophila Isolates
AAC Accepts, published online ahead of print on 27 October 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.04006-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 In vitro
More informationBradley A. Sharpe, M.D. Associate Professor Medicine Department of Medicine UCSF -- William Osler, M.D.
Bradley A. Sharpe, M.D. Associate Professor Medicine Department of Medicine UCSF sharpeb@medicine.ucsf.edu a. An ailment that often leads to suffocation and death. b. A friend of the aged. c. A common
More informationSurveillance of invasive pneumococcal infection in Belgium
Surveillance of invasive pneumococcal infection in Belgium National Reference Laboratory Start in 198 Laboratory Microbiology UH Leuven (prof. J. Vandepitte) Capsular type determination Antibiotic susceptibility
More informationPatterns of Resolution of Chest Radiograph Abnormalities in Adults Hospitalized with Severe Community-Acquired Pneumonia
MAJOR ARTICLE Patterns of Resolution of Chest Radiograph Abnormalities in Adults Hospitalized with Severe Community-Acquired Pneumonia Anke H. W. Bruns, 1 Jan Jelrik Oosterheert, 1 Mathias Prokop, 2 Jan-Willem
More informationCommunity-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome
ORIGINAL ARTICLE INFECTIOUS DISEASES Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome D. Sousa 1, I. Justo 1, A. Domínguez 2,3, A. Manzur 4,
More informationThe Importance of Appropriate Treatment of Chronic Bronchitis
...CLINICIAN INTERVIEW... The Importance of Appropriate Treatment of Chronic Bronchitis An interview with Antonio Anzueto, MD, Associate Professor of Medicine, University of Texas Health Science Center,
More informationPractice Guidelines for the Management of Community-Acquired Pneumonia in Adults
000 GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults John G. Bartlett, 1 Scott F. Dowell, 2 Lionel A. Mandell,
More informationWithin the past decade, the number of
CME EARN CATEGORY I CME CREDIT by reading this article and the article beginning on page 48 and successfully completing the posttest on page 53. Successful completion is defined as a cumulative score of
More informationCommunity-Acquired Pneumonia. Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital. Nothing to disclose.
Community-Acquired Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Nothing to disclose. Community-Acquired Pneumonia Talk will focus on adults Guideline
More informationCommunity Acquired Pneumonia
April 2014 References: 1. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL Mace SE, McCracken Jr. GH, Moor MR, St. Peter SD, Stockwell JA, and Swanson JT. The Management of
More informationPneumonia and influenza combined are the fifth leading
Community-Acquired Pneumonia in Older Veterans: Does the Pneumonia Prognosis Index Help? Lona Mody, MD,* Rongjun Sun, PhD, and Suzanne Bradley, MD* OBJECTIVES: Mortality rates from pneumonia increase steadily
More informationInvestigation and Management of Community-Acquired Pneumonia (CAP) Frequently Asked Questions
Investigation and Management of Community-Acquired Pneumonia (CAP) Frequently Asked Questions 1. Why was this algorithm developed? Emergency department physicians were seeking guidance about best antimicrobial
More informationPulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes
ORIGINAL ARTICLE INFECTIOUS DISEASES Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes C. Cillóniz 1,2,3, S. Ewig 4, E. Polverino 1,2,3, C. Muñoz-Almagro
More informationMædica - a Journal of Clinical Medicine
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Mortality Risk and Etiologic Spectrum of Community-acquired Pneumonia in Hospitalized Adult Patients Cornelia TUDOSE, Assistant Professor of Pneumology;
More informationBackground. Background. Background 3/14/2014. Conflict of Interest Statement:
Platform Presentations Comparison of zolpidem to other drugs associated with falls in hospitalized patients Ed Rainville, MSPharm. Conflict of Interest Statement: The speaker has no conflict of interest
More informationPatient information: Pneumonia in adults (Beyond the Basics)
Page 1 of 8 Official reprint from UpToDate www.uptodate.com 2014 UpToDate Patient information: Pneumonia in adults (Beyond the Basics) Authors Thomas J Marrie, MD Thomas M File, Jr, MD Section Editor John
More informationPULMONARY MEDICINE BOARD REVIEW. Financial Conflicts of Interest. Question #1: Question #1 (Cont.): None. Christopher H. Fanta, M.D.
PULMONARY MEDICINE BOARD REVIEW Christopher H. Fanta, M.D. Pulmonary and Critical Care Division Brigham and Women s Hospital Partners Asthma Center Harvard Medical School Financial Conflicts of Interest
More informationUPDATE IN HOSPITAL MEDICINE
UPDATE IN HOSPITAL MEDICINE FLORIDA CHAPTER ACP MEETING 2016 Himangi Kaushal, M.D., F.A.C.P. Program Director Memorial Healthcare System Internal Medicine Residency DISCLOSURES None OBJECTIVES Review some
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationMANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA IN THE ASIA PACIFIC REGION
MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA IN THE ASIA PACIFIC REGION Chong-Kin LIAM Department of Medicine Faculty of Medicine University of Malaya Kuala Lumpur liamck@ummc.edu.my COMMUNITY ACQUIRED PNEUMONIA
More informationStability in community-acquired pneumonia: one step forward with markers?
1 Servicio de Neumología. Universitary Hospital La Fe, Ciber de enfermedades respiratorias (CIBERES),Valencia, Spain; 2 Servicio de Infecciosas, Hospital Clinic, IDIBAPS, Barcelona, Spain; 3 Servicio de
More informationThe McMaster at night Pediatric Curriculum
The McMaster at night Pediatric Curriculum Community Acquired Pneumonia Based on CPS Practice Point Pneumonia in healthy Canadian children and youth and the British Thoracic Society Guidelines on CAP Objectives
More informationChapter 22. Pulmonary Infections
Chapter 22 Pulmonary Infections Objectives State the incidence of pneumonia in the United States and its economic impact. Discuss the current classification scheme for pneumonia and be able to define hospital-acquired
More informationPNEUMONIA IN CHILDREN. IAP UG Teaching slides
PNEUMONIA IN CHILDREN 1 INTRODUCTION 156 million new episodes / yr. worldwide 151 million episodes developing world 95% in developing countries 19% of all deaths in children
More informationPneumonia Severity Scores:
Pneumonia Severity Scores: Are they Accurate Predictors of Mortality? JILL McEWEN, MD FRCPC Clinical Professor Department of Emergency Medicine University of British Columbia Vancouver, BC Canada President,
More informationGuidelines/Guidance/CAP/ Hospitalized Child. PHM Boot Camp 2014 Jay Tureen, MD June 19, 2014
Guidelines/Guidance/CAP/ Hospitalized Child PHM Boot Camp 2014 Jay Tureen, MD June 19, 2014 CAP in Children: Epi Greatest cause of death in children worldwide Estimated > 2 M deaths in children In developed
More informationTo develop guidelines for the use of appropriate antibiotics for adult patients with CAP and guidance on IV to PO conversion.
Page 1 of 5 TITLE: COMMUNITY-ACQUIRED PNEUMONIA (CAP) EMPIRIC MANAGEMENT OF ADULT PATIENTS AND IV TO PO CONVERSION GUIDELINES: These guidelines serve to aid clinicians in the diagnostic work-up, assessment
More informationSunkaru Touray 1,2, Michael C Newstein 1,2, Justin K Lui 1,2, Maureen Harris 2 and Kim Knox 2
554673SMO0010.1177/2050312114554673SAGE Open MedicineTouray et al. research-article2014 Original Article SAGE Open Medicine Legionella pneumophila cases in a community hospital: A 12-month retrospective
More informationStudy objective: To investigate the clinical presentation of community-acquired Chlamydia
Clinical Presentation of Community- Acquired Chlamydia pneumoniae Pneumonia in Adults* Naoyuki Miyashita, MD, PhD; Hiroshi Fukano, MD; Niro Okimoto, MD, PhD, FCCP; Hiroki Hara, MD, PhD, FCCP; Koichiro
More informationETIOLOGIES AND TREATMENT OUTCOMES IN PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) AT SRINAGARIND HOSPITAL, KHON KAEN, THAILAND
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH ETIOLOGIES AND TREATMENT OUTCOMES IN PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) AT SRINAGARIND HOSPITAL, KHON KAEN, THAILAND Wipa Reechaipichitkul
More information